Allison Tolman, | |
6198 S 46th E, Idaho Falls, ID 83406-8248 | |
(307) 272-7801 | |
Not Available |
Full Name | Allison Tolman |
---|---|
Gender | Female |
Speciality | Lactation Consultant, Non-rn |
Location | 6198 S 46th E, Idaho Falls, Idaho |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1871162446 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | 14795 (Idaho) | Secondary |
174N00000X | Lactation Consultant, Non-rn | L-302491 (Idaho) | Primary |
Mailing Address | Practice Location Address |
---|---|
Allison Tolman, 6198 S 46th E, Idaho Falls, ID 83406-8248 Ph: () - | Allison Tolman, 6198 S 46th E, Idaho Falls, ID 83406-8248 Ph: (307) 272-7801 |
News Archive
Perhaps one of the most defining features of humanity is our capacity for empathy - the ability to put ourselves in others' shoes. A new University of Virginia study strongly suggests that we are hardwired to empathize because we closely associate people who are close to us - friends, spouses, lovers - with our very selves.
Astellas Pharma Canada, Inc. has announced that it has received approval from Health Canada for a new indication for its topical eczema therapy, Protopic® (tacrolimus ointment 0.03% and 0.1%). The new indication means that tacrolimus ointment can be prescribed for maintenance therapy to prevent flares and prolong flare free intervals in patients with moderate to severe atopic dermatitis (commonly called eczema).
A group of renowned COVID-19 experts including researchers from the Complexity Science Hub Vienna (CSH) call for a strong and coordinated European response with clearly defined goals to avoid ping-pong infection.
Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).
Genoptix, Inc., a specialized laboratory services provider, today announced that it ranked number 41 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the five year period from 2005–2009. Genoptix grew 3,451 percent during this period.
› Verified 8 days ago